Key Dates

Related Announcements

NOT-CA-24-067 - Request for Information (RFI): Seeking Input on Existing Study Populations with Germline Results and Samples Available for Multi-Cancer Detection (MCD) Assay Testing

NOT-CA-24-051 - Request for Information (RFI): Seeking Input on Existing Study Populations with Germline Results and Samples Available for Multi-Cancer Detection (MCD) Assay Testing

NOT-CA-24-046 - Request for Information (RFI): Seeking Input on Existing Study Populations with Multi-Cancer Detection (MCD) Test Results and Available Samples for Germline Testing.

RFA-CA-23-020 NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required)

RFA-CA-23-021 NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required)

RFA-CA-23-022 NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required)

NOT-CA-22-033 Request for Information (RFI): Seeking Input from Multi-Cancer Early Detection Test Developers on Readiness for Participation in an NCI-Sponsored Clinical Utility Randomized Controlled Screening Trial

Issued by

National Cancer Institute (NCI)

Purpose

This workshop will explain the method of engagement for assay developers interested in having their assays considered for selection to the Vanguard study.

Overview

This interactive virtual workshop is designed for multi-cancer detection (MCD) assay developers interested in participating in trials and studies to be run by a new Cancer Screening Research Network (CSRN) that NCI is establishing. NCI recognizes the importance of this new technology and is interested in assessing the use of MCD assays as cancer screening tools. The CSRN is anticipated to start in January 2024 and its initial effort will be launching the Vanguard study (RFA-CA-23-020, RFA-CA-23-021, RFA-CA-23-022).

NCI will outline the steps involved in selecting assays for use in the Vanguard study. After interested companies submit their assay information, NCI will select some of these companies to participate in independent verification of their assays’ performance characteristics. NCI anticipates selecting two assays for use in the Vanguard study. Assays not selected for the Vanguard study may be considered for future CSRN studies.

NCI recognizes the importance of the legal and contractual aspects of engaging with assay developers. Therefore, one hour of this meeting will be dedicated to discussing material transfer agreements, data-sharing expectations, and clinical trial agreements between NCI and MCD assay developers.

For additional information on NCI’s research activities in cancer screening, please visit the MCD research and CSRN websites.

Webinar Information

Wednesday, May 3, 2023, 1:00 pm-5:00 pm ET

Pre-registration is required to join this webinar.

To pre-register, please use this link: https://events.cancer.gov/dcp/mcdengagement/registration 

Inquiries

Please direct all inquiries to:

Paul Pinsky, Ph.D.
National Cancer Institute (NCI)
240-276-7014
Email: [email protected]

Elyse LeeVan, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-7314
Email: [email protected]